Fennec Pharmaceuticals (FENC) EBIT (2010 - 2025)
Fennec Pharmaceuticals posted quarterly EBIT of $2.2 million for Q4 2025, up 336.94% year-on-year from $506479.3 in Q4 2024, and up 1270.9% on a QoQ basis from -$189000.0 in Q3 2025.
Fennec Pharmaceuticals (FENC) has 16 years of EBIT data on file, last reported at $2.2 million in Q4 2025.
- For the quarter ending Q4 2025, EBIT rose 336.94% year-over-year to $2.2 million; the trailing twelve-month figure through Dec 2025 stood at -$1.5 million (down 159.03% YoY), and the FY2025 full-year result was -$1.5 million, down 159.0% from the prior year.
- EBIT for Q4 2025 stood at $2.2 million, up from -$189000.0 in the prior quarter.
- Across five years, EBIT topped out at $13.7 million in Q1 2024 and bottomed at -$7.9 million in Q3 2022.
- The 5-year median for EBIT is -$4.0 million (2021), against an average of -$2.6 million.
- Peak annual rise in EBIT reached 360.78% in 2024, while the deepest fall reached 411.5% in 2024.
- A 5-year view of EBIT shows it stood at -$4.2 million in 2021, then plunged by 45.83% to -$6.1 million in 2022, then soared by 70.37% to -$1.8 million in 2023, then jumped by 48.62% to -$934000.0 in 2024, then jumped by 336.94% to $2.2 million in 2025.
- The last three EBIT figures came in at $2.2 million (Q4 2025), -$189000.0 (Q3 2025), and -$2.7 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Fennec Pharmaceuticals | 281.48 Mn | 244.70 Mn | 7.67 Mn | 2.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.21 Mn |
| Sep 30, 2025 | -189,000.00 |
| Jun 30, 2025 | -2.73 Mn |
| Mar 31, 2025 | -808,000.00 |
| Dec 31, 2024 | -934,000.00 |
| Sep 30, 2024 | -5.20 Mn |
| Jun 30, 2024 | -5.04 Mn |
| Mar 31, 2024 | 13.74 Mn |
| Dec 31, 2023 | -1.82 Mn |
| Sep 30, 2023 | -1.02 Mn |
| Jun 30, 2023 | -4.67 Mn |
| Mar 31, 2023 | -5.27 Mn |
| Dec 31, 2022 | -6.14 Mn |
| Sep 30, 2022 | -7.90 Mn |
| Jun 30, 2022 | -5.01 Mn |
| Mar 31, 2022 | -3.55 Mn |
| Dec 31, 2021 | -4.21 Mn |
| Sep 30, 2021 | -4.17 Mn |
| Jun 30, 2021 | -3.92 Mn |
| Mar 31, 2021 | -4.92 Mn |
| Dec 31, 2020 | -3.35 Mn |
| Sep 30, 2020 | -5.86 Mn |
| Jun 30, 2020 | -4.85 Mn |
| Mar 31, 2020 | -3.84 Mn |
| Dec 31, 2019 | -3.65 Mn |
| Sep 30, 2019 | -1.86 Mn |
| Jun 30, 2019 | -4.81 Mn |
| Mar 31, 2019 | -2.68 Mn |
| Dec 31, 2018 | -3.11 Mn |
| Sep 30, 2018 | -2.85 Mn |
| Jun 30, 2018 | -2.67 Mn |
| Mar 31, 2018 | -1.79 Mn |
| Dec 31, 2017 | -2.52 Mn |
| Sep 30, 2017 | -2.19 Mn |
| Jun 30, 2017 | -1.48 Mn |
| Mar 31, 2017 | -771,000.00 |
| Dec 31, 2016 | -1.15 Mn |
| Sep 30, 2016 | -564,000.00 |
| Jun 30, 2016 | -707,000.00 |
| Mar 31, 2016 | -454,000.00 |
| Dec 31, 2015 | -551,000.00 |
| Sep 30, 2015 | -338,000.00 |
| Jun 30, 2015 | -549,000.00 |
| Mar 31, 2015 | -452,000.00 |
| Dec 31, 2014 | -791,000.00 |
| Sep 30, 2014 | -619,000.00 |
| Jun 30, 2014 | -930,000.00 |
| Mar 31, 2014 | -537,000.00 |
| Dec 31, 2013 | -416,000.00 |
| Sep 30, 2013 | -51,000.00 |
| Jun 30, 2013 | -927,000.00 |
| Mar 31, 2013 | -537,000.00 |
| Dec 31, 2012 | -1.12 Mn |
| Sep 30, 2012 | -630,000.00 |
| Jun 30, 2012 | -1.25 Mn |
| Mar 31, 2012 | -616,000.00 |
| Dec 31, 2011 | -902,000.00 |
| Sep 30, 2011 | -944,000.00 |
| Jun 30, 2011 | -572,000.00 |
| Mar 31, 2011 | -1.02 Mn |
| Dec 31, 2010 | -816,000.00 |
| Sep 30, 2010 | -917,000.00 |
| Jun 30, 2010 | -2.51 Mn |